deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 9-arm NCT03136185

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Conditions Myelofibrosis Post-essential Thrombocythemia Myelofibrosis (PET-MF) Post-polycythemia Vera Myelofibrosis (PPV-MF) Primary Myelofibrosis (PMF)
Interventions Bomedemstat
Updated 18 times since 2017 Last updated: Dec 19, 2023 Started: Jul 18, 2017 Primary completion: Mar 8, 2022 Completion: Mar 8, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis (PET-MF) and is currently completed. Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Sep 2019 · 6 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Dec 2023 · 5 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Phase: PHASE2 → PHASE1_PHASE2

  4. Dec 2023 — Feb 2024 [monthly]

    Completed PHASE2

  5. Jul 2023 — Dec 2023 [monthly]

    Completed PHASE2

▶ Show 13 earlier versions

  1. Mar 2023 — Jul 2023 [monthly]

    Completed PHASE2

  2. Apr 2022 — Mar 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

    Phase: PHASE1 → PHASE2

  10. Sep 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  11. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  12. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  13. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Data source: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations